Rifaximin Redux: Treatment of recurrent Clostridium difficile infections with Rifaximin immediately post-vancomycin treatment

被引：91

作者：

Johnson, Stuart ^{[1
,2
,3
]}

Schriever, Christopher ^{[3
]}

Patel, Ursula ^{[1
,2
]}

Patel, Toral ^{[3
]}

Hecht, David W. ^{[1
,2
,3
]}

Gerding, Dale N. ^{[1
,2
,3
]}

机构：

[1] Edward Hines Jr VA Hosp, Res Serv, Hines, IL 60141 USA

[2] Edward Hines Jr VA Hosp, Med Serv, Hines, IL 60141 USA

[3] Loyola Univ, Med Ctr, Infect Dis Sect, Maywood, IL 60153 USA

来源：

ANAEROBE | 2009年 / 15卷 / 06期

关键词：

Clostridium difficile; Rifaximin; Vancomycin; PLACEBO-CONTROLLED TRIAL; DIARRHEA;

D O I：

10.1016/j.anaerobe.2009.08.004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We report our continued experience with rifaximin as a post-vancomycin treatment strategy in six patients with multiple recurrences of C difficile infection (CDI). Four of the six patients (67%) had no further diarrhea episodes, but two patients failed shortly after or during the rifaximin treatment. C. difficile isolates from one of the two patients who failed treatment had an MIC of >256 ug/ml to rifampin. Serial therapy with vancomycin, followed by rifaximin remains an option for some patients with multiple CDI recurrences. Published by Elsevier Ltd.

引用

页码：290 / 291

页数：2

共 8 条

[1] A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea [J].

DuPont, HL ;

Jiang, ZD ;

Okhuysen, PC ;

Ericsson, CD ;

de la Cabada, FJ ;

Ke, S ;

DuPont, MW ;

Martinez-Sandoval, F .

ANNALS OF INTERNAL MEDICINE, 2005, 142 (10) :805-812

[2] Rifaximin in Treatment of Recurrent Clostridium difficile-associated Diarrhea: An Uncontrolled Pilot Study [J].

Garey, Kevin W. ;

Jiang, Zhi-Dong ;

Bellard, Angelle ;

DuPont, Herbert L. .

JOURNAL OF CLINICAL GASTROENTEROLOGY, 2009, 43 (01) :91-93

[3] In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004 [J].

Hecht, David W. ;

Galang, Minerva A. ;

Sambol, Susan P. ;

Osmolski, James R. ;

Johnson, Stuart ;

Gerding, Dale N. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (08) :2716-2719

[4] In vitro activity and fecal concentration of rifaximin after oral administration [J].

Jiang, ZD ;

Ke, S ;

Palazzini, E ;

Riopel, L ;

Dupont, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2205-2206

[5] TREATMENT OF ASYMPTOMATIC CLOSTRIDIUM-DIFFICILE CARRIERS (FECAL EXCRETORS) WITH VANCOMYCIN OR METRONIDAZOLE - A RANDOMIZED, PLACEBO-CONTROLLED TRIAL [J].

JOHNSON, S ;

HOMANN, SR ;

BETTIN, KM ;

QUICK, JN ;

CLABOTS, CR ;

PETERSON, LR ;

GERDING, DN .

ANNALS OF INTERNAL MEDICINE, 1992, 117 (04) :297-302

[6]

JOHNSON S, 2009, INT J ANTIMICROB AGE

[7] Interruption of recurrent Clostridium difficile -: Associated diarrhea episodes by serial therapy with vancomycin and rifaximin [J].

Johnson, Stuart ;

Schriever, Christopher ;

Galang, Minerva ;

Kelly, Ciaran P. ;

Gerding, Dale N. .

CLINICAL INFECTIOUS DISEASES, 2007, 44 (06) :846-848

[8] Rifampin and rifaximin resistance in clinical isolates of Clostfdium diicile [J].

O'Connor, Jennifer R. ;

Galang, Minerva A. ;

Sambol, Susan P. ;

Hecht, David W. ;

Vedantam, Gayatri ;

Gerding, Dale N. ;

Johnson, Stuart .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (08) :2813-2817

← 1 →